ReviewChinese clinical oncology2022
Artificial intelligence and imaging for risk prediction of pancreatic cancer: a narrative review.
Review in Chinese clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Pancreatic Cancer Resectability After Neoadjuvant Treatment: An Imaging Challenge.Diagnostics (Basel, Switzerland) · 2025Review
- Review
- Pancreatic Ductal Adenocarcinoma (PDAC): A Review of Recent Advancements Enabled by Artificial Intelligence.Cancers · 2024Review
- Advanced Data Processing of Pancreatic Cancer Data Integrating Ontologies and Machine Learning Techniques to Create Holistic Health Records.Sensors (Basel, Switzerland) · 2024Article
- Review
- Pancreatic Adenocarcinoma: Imaging Modalities and the Role of Artificial Intelligence in Analyzing CT and MRI Images.Diagnostics (Basel, Switzerland) · 2024Review
- Pancreatic Ductal Adenocarcinoma: Update of CT-Based Radiomics Applications in the Pre-Surgical Prediction of the Risk of Post-Operative Fistula, Resectability Status and Prognosis.Journal of clinical medicine · 2023Review
- Artificial intelligence as a noninvasive tool for pancreatic cancer prediction and diagnosis.World journal of gastroenterology · 2023Review
- Review
- Segmentation of Pancreatic Subregions in Computed Tomography Images.Journal of imaging · 2022Article
- Risk prediction of pancreatic cancer using AI analysis of pancreatic subregions in computed tomography images.Frontiers in oncology · 2022Article
- Prediction Performance of Deep Learning for Colon Cancer Survival Prediction on SEER Data.BioMed research international · 2022Article
- Risk Assessment and Radiomics Analysis in Magnetic Resonance Imaging of Pancreatic Intraductal Papillary Mucinous Neoplasms (IPMN).Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo emphasize the importance of pancreatic imaging and the application of artificial intelligence (AI) for enhanced risk prediction of pancreatic ductal adenocarcinoma (PDAC).
backgroundDetecting PDAC at the early stage is challenging as the disease either remains asymptomatic or presents nonspecific symptoms. Risk prediction of PDAC is an efficient strategy as subsequent targeted screening can assist in diagnosing cancer at the early stage even before the symptoms appear. However, the lack of specific clinical and epidemiological predictors of PDAC makes prediction a highly challenging task. Detecting precursor changes in the pancreas can potentially assist in the risk prediction of PDAC as the precancerous pancreas evolves through biological adaptations-presented as morphological and textural changes on abdominal imaging. However, such microlevel "clues" usually remain unnoticed or unappreciated, partly due to the unavailability of tools to detect and interpret such complex measurements, making the risk prediction of PDAC an unresolved problem.
methodsThis review study highlights the limitations of the current risk prediction models of PDAC and the importance of abdominal imaging for predicting PDAC. A suggestive narrative is made as to how recent AI tools can assist in extracting precise measurements of biomarkers, detecting early signs and precancerous abnormalities, quantifying tissue characteristics, and revealing complex features potentially indicative of future incidence of pancreatic cancer (PC) using abdominal imaging. With the help of peer examples of other cancers, a case is built about the application of AI in utilizing image features of the pancreas to enhance risk prediction of PDAC. Furthermore, the challenges of AI applications including insufficient data for model training, risk of data privacy violation, inconsistent data labeling, and limited computational resources, and their potential solutions are also discussed.
conclusionsThe recent advancement in the domain of AI is a potential opportunity to utilize automated tools for the identification of imaging-based indicators of PDAC and perform enhanced risk prediction of cancer. With this awareness and motivation, better management of PDAC has expected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.